Arcutis Biotherapeutics, Inc. ARQT

$ARQT ARQT Earnings Forecast
Next quarter’s earnings estimate for ARQT is -$0.41 with a range of -$0.44 to -$0.38. The previous quarter’s EPS was -$0.42. ARQT beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year ARQT has Outperformed its overall industry.

$ARQT Waste time on you? Nah

$ARQT Taking into account the latest results, the most recent consensus for Arcutis Biotherapeutics from six analysts is for revenues of US$166.5m in 2024. If met, it would imply a substantial 26% increase on its revenue over the past 12 months. Losses are supposed to decline, shrinking 12% from last year to US$1.49. Before this latest report, the consensus had been expecting revenues of US$164.4m and US$1.70 per share in losses. While the revenue estimates were largely unchanged, sentiment seems to have improved, with the analysts upgrading their numbers and making a cut to losses per share in particular.

Zacks is reporting an earnings miss and downgraded it to hold. Wtf.

Because the 24% short on float will keep this down until they are tired of it.

Everything is green but this stock. I’m getting tired of this pos.

Let’s go this will be huge on Monday

Apextradez.com

Padagis lawsuits results scheduled for August 8th.

OMGA ??????